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Granulocyte / macrophage - colony-stimulating factor 
(GM-CSF), an immunomodulator of hematopoietic 
cells, has also been shown to stimulate human kerati-
nocyte proliferation in vitro and speed healing of 
wounds in the skin oflepromatous leprosy patients. In 
this study we have examined the in vivo effects of re-
combinant human GM-CSF on epidermal keratino-
cyte proliferation and on expression of proteins mark-
ing regenerative epidermal growth. Skin biopsies 
from GM-CSF injected cutaneous sites were obtained 
between 1 and 6 d following administration of7.5 or 15 
ILg of the growth factor. Activation of keratinocyte 
proliferation, quantified as the expression of the Ki67+ 
nuclear antigen, was noted 1 d following GM-CSF ad-
G ranuloctye/macrophage-colony-stimulating factor (GM-CSF) is a 23-kd glycoprotein that regulates the proliferation and differentiation of hematopoietic cells [1]. GM-CSF also plays a significant role as an immunomodulator, activating macrophages, thus 
promoting the killing of intracellular pathogens [2]. In addition, the 
cytokine mediates the maturation of epidermal Langerhans cells and 
bone marrow - derived dendritic cells [3 - 5]. Recently we demon-
strated that GM-CSF stimulates keratinocyte proliferation ill vitro 
and speeds healing of skin wounds in lepromatous leprosy patients 
[6,7]' 
Normal human epidermis displays two alternative states ofkerat-
inocyte growth and differentiation: 1) a "normal" state oflow-level 
proliferation and ordered differentiation to maintain tissue homeo-
stasis, and 2) a "regenerative" or "alternative" pathway of increased 
proliferation and more rapid cellular maturation that is associated 
with healing of skin wounds and a variety of hyperproliferative 
epidermal pathologies. The "regenerative" keratinization path~ay 
outlined by Mansbridge et al [8] highlighted the altered expressIOn 
of several structural keratinocyte proteins detected by indirect im-
munofluorescence or immunoperoxidase antibody staining during 
wound healing and in psoriatic epidermis. Altered expression of 
involucrin, filaggrin, and keratins 6/16 mark the "alternative" 
maturation pathway of keratinocytes associated with this regenera-
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ministration. A regenerative epidermal phenotype, 
demonstrated by immunohistochemical staining of 
cellular proteins involucrin, filaggrin, and keratin 16, 
was similarly noted as early as 1 d following GM-CSF 
injection. This phenotype persisted as late as 6 d post-
injection. These results suggest that GM-CSF injection 
into human skin induces keratinocyte proliferation as 
well as regenerative differentiation of the epidermis. 
To date no other cytt>kine has been shown to be mito-
genic for human keratinocytes both in vivo and in vitro 
or to alter keratinocyte differentiation along the "al-
ternate" or regenerative pathway. ] Invest Dermatol 
103:601-604,1994 
tive epidermal phenotype [8]. Ki67, a nuclear antigen, has been 
demonstrated to be an active marker of cellular proliferation [9,10] . 
The antigen is normally absent in quiescent cells but is expressed in 
proliferating cells during the S, G2, and M phases of the cell cycle 
lll]. In the present study we have directly evaluated the effect of 
GM-CSF injection into the skin oflepromatous patients on kerati-
nocyte maturation and proliferation. Our results suggest GM-CSF 
directly affects keratinocyte proliferation and regenerative differen-
tiation of the epidermis. 
MATERIALS AND METHODS 
Patients Twenty patients with lepromatous leprosy were selected for 
GM-CSF administration as previously described [7]. 
Study Design Patients were seen at the Clinical Branch of the Leonard 
Wood Memorial Center for Leprosy Research, Cebu City, Philippines [7J. 
Recombinant GM-CSF was supplied by Sandoz AG (Basel, Switzerland). 
Intradermal injections of either 7.511g or 15.0 I1g of GM-CSF produced in 
CHO cells (GM 89-107) (batch 4026 0188) were administered daily as 
described [7]. Patients were randomly assigned to receive a repeated injection 
of GM-CSF at a previously administered site. A 4-mm punch biopsy was 
taken on entry to the srudy. Injection site biopsies were performed at specific 
time intervals after GM-CSF administration. All 20 patients were biopsied at 
time O. Four patients were biopsied after 24 11, five after 48 h, four after 72 
and 96 h, and three after 120-144 h. Ten additional biopsies were per-
formed on patients who underwent reinjection. A final biopsy was taken 
from an uninvolved site on day 11. All injections were given in skin of the 
back of patients [7]. 
hnmunohistochemistry Biopsy specimens were fixed in neutral buf-
fered 10% formalin overnight, embedded in paraffin, and sectioned. Sec-
tions were deparaflinized in xylene and decreasing concentrations of ethanol 
mixed with phosphate-buffered saline solution (PBS). Two distinct immu-
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noperoxidase techniques were initially performed. The specimens to be 
stained with the Ki67 nuclear antibody (AMAC, Inc., Westbrook, Maine) 
underwent trypsinization for 10 min and were fixed in cold, 100% acetone. 
Activation of cellular proliferation was quantified by the counting ofkerati-
nocytes expressing Ki67+ nuclei located in the basal or immediately supra-
basal epidermis and presented as a percentage of 100 total basal cells. Speci-
mens to be examined for keratinocyte cytoplasmic proteins were fixed with 
acetone:methanol, 1:1. The antibodies directed against filaggrin and involu-
crin [8] were obtained from Biomedical Technology, Inc., MA. Monoclonal 
antibody AE-1 was a generous donation from Dr. T.-T. Sun. The regenera-
tive maturation phenotype was defined as premature expression of filaggrin 
and involucrin by lower spinous keratinocytes and induced expression of 
keratin 16 (detected by antibody AE-1). lmmunoperoxidase studies were 
performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, 
CAl as described previously [12,13]' Negative controls were performed for 
all immunoperoxidase studies. 
Determination of Epidermal Thickness Epidermal thickness was 
evaluated by direct examination of hematoxylin-stained sections using a 
computer-based image digitizing system (Southern Micro Instruments, Inc., 
Atlanta, GA) [7]. 
Statistical Analysis Biopsy specimens were divided into pre- and post-
treatment groups. Differences in the incidence of Ki67+ cells and the ex-
pression of a regenerative maturation phenotype were analyzed using a 
chi-square model. 
RESULTS 
Injection of GM-CSF intradermally into the skin of patients with 
lepromatous leprosy produced epidermal thickening (acanthosis) 
that peaked by 24 - 48 h, persisted for up to 6 d after injection, and 
had returned fully to basal levels by 11 d (Fig IA). To establish 
whether acanthosis was the result of keratinocyte hyperplasia, hy-
pertrophy, or a combination of the two, skin section sites were 
stained with antibodies detecting the nuclear antigen Ki67 (hyper-
plasia) and the cellular proteins filaggrin, involucrin, and keratin 16. 
Intradermal injection of human rGM-CSF increased keratinocyte 
proliferation as demonstrated by an enhanced number of Ki67+ 
keratinocytes in the epidermis. The number ofKi67+ keratinocytes 
was enhanced by 24 h and peaked within 48 h after rGM-CSF 
injection (Fig IB). There were still substantial increases in the 
number of Ki67+ nuclei after 96 h. 
Because the peak of epidermal thickening preceded peak kerati-
nocyte proliferation, we examined the role ofkeratinocyte differen-
tiation in GM-CSF-induced epidermal acanthosis. The ability of 
rGM-CSF injection to induce regenerative maturation was assessed 
by staining with antibodies directed against filaggrin, a protein nor-
mally associated with keratin filaments in keratohyaline granules, 
and involucrin, a membrane protein crosslinked by transglutamin-
ase as part of normal keratinocyte terminal differentiation. Al-
though these cellular proteins are normally expressed in the granu-
lar layer of the epidermis, premature expression of filaggrin and 
involucrin occurs in lower spinous keratinocytes in regenerating 
epidermis. Increased premature expression of filaggrin was ob-
served as early as 1 dafter rGM-CSF injection (Fig Ie). Similarly, 
the incidence of premature expression of involucrin in lower spi-
nous keratinocytes was also noted as early as 1 d after the adminis-
tration of rGM-CSF (Fig Ie). The increased presence of confluent 
regenerative maturation was detected for both involucrin (p = 
0.009) and filaggrin (p = 0.067) following GM-CSF administra-
tion. The expression of AE-l reactive keratins in intrafollicular 
keratinocytes was absent prior to GM-CSF injection; however, sev-
eral patients demonstrated focal induced expression of the keratin-
16 protein following cytokine administration (see below). 
Figure 2 illustrates the histologic staining patterns of Ki67+ 
keratinocyte nuclei, involucrin, filaggrin, and keratin 16 in skin 
following GM-CSF injection. A single injection of rGM-CSF re-
sulted in keratinocyte activation in vivo as evidenced by increased 
proliferation and increased expression of the regenerative matura-
tion phenotype. This growth-activated phenotype is identical to 
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Figure 1. Effects of GM-CSF on human epidermis in vivo. A) Epider-
mal thickness in control skin (day 0) or following intradermal GM-CSF 
injection (days 1-4), expressed as average thickness in microns. B) Kerati-
nocyte proliferation in control skin (day 0) or following GM-CSF injection 
(days 1-4), as determined from the percentage of basal keratinocytes ex-
pressing the Ki67 nuclear protein. C) Expression of involucrin (solid bars) or 
filaggrin (hatched bars) in a pattern of regenerative epidermal growth/ma-
turation as assessed in control skin (day 0) or following GM-CSF injection 
(days 1-4). 
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Figure 2. GM-CSF alters expression of proliferation and differentiation-associated proteins in human epidermis after in vivo administration. 
Histologic sections showing histochemical detection of the Ki67 protein (A,B); involucrin (C,D); filaggrin (E,F) , or keratin 16 (G,H) in control (pre-injec-
tion) skin (lift column: A,C,E,G) or in sites following intradermal GM-CSF injection (right colllm'l: B,D,F,H). Involucrin staining in D is shown 1 dafter 
GM-CSF administration, whereas Ki67 (B), lilaggrin (F), and keratin 16 (H) are shown 3 d following GM-CSF administration (arrows, positive staining 
reactions in GM-CSF injected sites). Faint-to-moderate pigmentation of basal keratinocyte cytoplasm is due to melanization in all micrographs shown. All 
micrographs are shown at the same magnification; bar in A, 200 j.lm. 
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DISCUSSION 
Because GM-CSF is produced not only by immune cells but also by 
keratinocytes [15], it is a potential autocrine or paracrine regulator 
of epidermal growth. Under normal conditions, keratinocyte GM-
CSF gene expression and production of GM-CSF are limited. How-
ever, under several conditions, including infection and tissue injury, 
the local production of interleukin 1 and tumor necrosis factor-a 
lead to increased expression of GM-CSF mRNA and increased pro-
duction of GM-CSF [16,17]. It is postulated that an increase in 
GM-CSF would result in increased wound healing, as well as acti-
vation of macrophages and Langerhans cells, thereby enhancing the 
host's local cellular immune defense. A common occurrence with 
therapeutic GM-CSF administration (intravenously or subcutane-
ously) is the occurrence of a disseminated cutaneous eruption char-
acterized by erythematous macules and papules [18]. Erythematous 
lesions also develop frequently at sites of subcutaneous GM-CSF 
injection [19]. Histopathologic characterization of the wide-spread 
lesions has shown a neutrophil-predominant infiltrate in the 
dermis, which is also accompanied by macrophage influx, epider-
mal intracellular adhesion molecule-l expression, epidermal 
edema, occasional keratinocyte dysplasia, and variable lymphocyte 
influx [18] . These effects clearly differ from those seen in this study 
in which intradermal GM-CSF administration produced primarily 
epidermal effects, in association with an influx of dermal Langer-
hans cells, but not appreciable increases in macrophages or T lym-
phocytes [7]. Some of the differences observed between studies may 
be related to larger quantities of GM-CSF used for agranulocytosis, 
to the route of GM-CSF administration, or to the disease back-
ground in which GM-CSF is administered. 
The results presented in this report demonstrate that a single 
intradermal injection of GM-CSF can alter keratinocyte prolifera-
tion and differentiation. As GM-CSF functions as a mitogen for 
human keratinocytes in culture [6], GM-CSF could function in 
human skin in .vivo as an epidermal mitogen, directly regulating 
proliferation and/or differentiation of keratinocytes. It should be 
acknowledged, however, that the effects of GM-CSF on epider-
mis could be mediated indirectly through secondary cytokines in-
duced by GM-CSF. For example, interleukin-6 is rapidly induced 
in some patients following GM-CSF administration [20]; inter-
leukin-6 is a mitogen for human keratinocytes in culture and in-
creased production is associated with keratinocyte hyperplasia in 
psoriasis, suggesting that it is also a candidate mitogen for human 
keratinocytes in intact epidermis [21]. GM-CSF does not increase 
transforming growth factor-a production by keratinocytes in an 
explant model [22] , nor does it increase epidermal growth factor 
receptor expression, suggesting that GM-CSF does not function as a 
pan-activator of autocrine growth circuits for epidermal keratino-
cytes. 
Previous studies have shown that physical trauma to the epider-
mis, e.g., the removal of the stratum corneum by tape-stripping, can 
induce the regenerative epidermal phenotype, an alternative path-
way of keratinocyte differentiation. Interestingly, this alternative 
pathway of keratinocyte differentiation is persistently present in 
uninjured epidermis associated with inflammatory skin pathologies 
such as psoriasis and lichen planus. Although keratinocyte prolifer-
ation is increased in many of these disorders and an increased abun-
dance of several cytokines has been noted, no molecular inducers of 
regenerative epidermal growth have previously been identified. 
The results of the present study identify GM-CSF as a probable 
regulator of regenerative epidermal growth, although other cyto-
kines might also induce this epidermal phenotype. The production 
of GM-CSF by numerous cellular elements associated with infil-
trating cells in skin wounds, psoriasis, and other inflammatory der-
matoses, suggests that GM-CSF could be the molecular link be-
tween cellular immune elements infiltrating skin and induction of 
an altered epidermal phenotype. GM-CSF may also have a potential 
therapeutic role in modifying the healing of acute or chronic skin 
wounds. 
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